A STING-adjuvanted outer membrane vesicle nanoparticle vaccine vs. Klebsiella pneumoniae elicits broad capsule-type cross-protection
PNAS Nexus · 07.04.2026 · 5 (4)
DOI: 10.1093/pnasnexus/pgag092 ↗Kurz gefasst
Fachartikel in der Zeitschrift PNAS Nexus, online erschienen am 30.03.2026. Verfasst von Hervé Besançon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, Swiss National Science Foundation Postdoctoral Fellowship, A.P. Giannini Foundation.
Abstract (Originalsprache)
Klebsiella pneumoniae (Kp) is a leading cause of hospital- and community-acquired infections and is increasingly resistant to last-line antibiotics, positioning it as a World Health Organization–designated priority pathogen. Vaccine development has been hindered by the extensive diversity of Kp exopolysaccharide capsules. We developed a cellular nanoparticle (CNP) platform in which bacterial outer membrane vesicles (OMVs) are stably coated onto a STING (stimulator of interferon genes)-adjuvanted nanoparticle core (CNP-KpSTING). The resulting ∼100-nm nanoparticles are homogenous and optimized for recruitment and activation of antigen-presenting cells in draining lymph nodes. CNP-KpSTING vaccination elicited robust antibody responses, enhanced neutrophil-mediated bacterial clearance, and conferred cross-protection against heterologous Kp capsule types in vitro and in lethal pneumonia models. Passive transfer of postvaccination sera reduced bacterial burden and inflammatory cytokines in the lungs of infected mice. These findings establish CNP-KpSTING as a versatile platform that addresses key antigenic barriers inherent to Kp and support OMV-CNPs as a promising foundation for broadly protective vaccines against multidrug-resistant gram-negative pathogens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA.
- Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA 92093, USA.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Hervé Besançon, Daniel Sun, Samuel Kim, Samira Dahesh, Shawn M Hannah, Liangfang Zhang, Victor Nizet, Elisabet Bjånes
Förderung
- NIAID NIH HHS
- Swiss National Science Foundation Postdoctoral Fellowship
- A.P. Giannini Foundation
- NIH
Zitieren
APA
Besançon, H., Sun, D., Kang, K., Kim, S., Dahesh, S., Morrill, S., Hannah, S. M., Ngo, A. T. P., Zhang, L., Nizet, V., & Bjånes, E. (2026). A STING-adjuvanted outer membrane vesicle nanoparticle vaccine vs. Klebsiella pneumoniae elicits broad capsule-type cross-protection. PNAS Nexus, 5(4). https://doi.org/10.1093/pnasnexus/pgag092
Vancouver
Besançon H, Sun D, Kang K, Kim S, Dahesh S, Morrill S, et al. A STING-adjuvanted outer membrane vesicle nanoparticle vaccine vs. Klebsiella pneumoniae elicits broad capsule-type cross-protection. PNAS Nexus. 2026;5(4). doi:10.1093/pnasnexus/pgag092
BibTeX
@article{Besanon2026,
author = {Besançon, Hervé and Sun, Daniel and Kang, Kalisa and Kim, Samuel and Dahesh, Samira and Morrill, Sydney and Hannah, Shawn M and Ngo, Anh T P and Zhang, Liangfang and Nizet, Victor and Bjånes, Elisabet},
title = {A STING-adjuvanted outer membrane vesicle nanoparticle vaccine vs. Klebsiella pneumoniae elicits broad capsule-type cross-protection},
journal = {PNAS Nexus},
year = {2026},
volume = {5},
number = {4},
doi = {10.1093/pnasnexus/pgag092}
}
EUVIMED